Department of Public Health Sciences, University of Alberta, Room 3021, Research Transition Facility, 8308 114 Street, Edmonton, Alberta, T6G 2V2, Canada.
BMC Gastroenterol. 2010 Sep 27;10:111. doi: 10.1186/1471-230X-10-111.
Recently, several new endoscopic treatments have been used to treat patients with Barrett's esophagus with high grade dysplasia. This systematic review aimed to determine the safety and effectiveness of these treatments compared with esophagectomy.
A comprehensive literature search was undertaken to identify studies of endoscopic treatments for Barrett's esophagus or early stage esophageal cancer. Information from the selected studies was extracted by two independent reviewers. Study quality was assessed and information was tabulated to identify trends or patterns. Results were pooled across studies for each outcome. Safety (occurrence of adverse events) and effectiveness (complete eradication of dysplasia) were compared across different treatments.
The 101 studies that met the selection criteria included 8 endoscopic techniques and esophagectomy; only 12 were comparative studies. The quality of evidence was generally low. Methods and outcomes were inconsistently reported. Protocols, outcomes measured, follow-up times and numbers of treatment sessions varied, making it difficult to calculate pooled estimates.The surgical mortality rate was 1.2%, compared to 0.04% in 2831 patients treated endoscopically (1 death). Adverse events were more severe and frequent with esophagectomy, and included anastomotic leaks (9.4%), wound infections (4.1%) and pulmonary complications (4.1%). Four patients (0.1%) treated endoscopically experienced bleeding requiring transfusions. The stricture rate with esophagectomy (5.3%) was lower than with porfimer sodium photodynamic therapy (18.5%), but higher than aminolevulinic acid (ALA) 60 mg/kg PDT (1.4%). Dysphagia and odynophagia varied in frequency across modalities, with the highest rates reported for multipolar electrocoagulation (MPEC). Photosensitivity, an adverse event that occurs only with photodynamic therapy, was experienced by 26.4% of patients who received porfimer sodium.Some radiofrequency ablation (RFA) or argon plasma coagulation (APC) studies (used in multiple sessions) reported rates of almost 100% for complete eradication of dysplasia. But the study methods and findings were not adequately described. The other studies of endoscopic treatments reported similarly high rates of complete eradication.
Endoscopic treatments offer safe and effective alternatives to esophagectomy for patients with Barrett's esophagus and high grade dysplasia. Unfortunately, shortcomings in the published studies make it impossible to determine the comparative effectiveness of each of the endoscopic treatments.
最近,几种新的内镜治疗方法已被用于治疗伴有高级别异型增生的 Barrett 食管患者。本系统评价旨在确定这些治疗方法与食管切除术相比的安全性和有效性。
我们进行了全面的文献检索,以确定 Barrett 食管或早期食管癌内镜治疗的研究。由两名独立的评审员提取所选研究的信息。评估研究质量并制表以确定趋势或模式。为每个结局汇总了来自研究的结果。比较了不同治疗方法的安全性(不良事件的发生)和有效性(异型增生的完全消除)。
符合选择标准的 101 项研究包括 8 种内镜技术和食管切除术;仅有 12 项为比较研究。证据质量普遍较低。方法和结局的报告不一致。方案、测量的结局、随访时间和治疗次数不同,难以计算汇总估计值。手术死亡率为 1.2%,而 2831 例内镜治疗患者为 0.04%(1 例死亡)。与内镜治疗相比,手术相关的不良事件更严重、更常见,包括吻合口漏(9.4%)、伤口感染(4.1%)和肺部并发症(4.1%)。4 例(0.1%)内镜治疗患者出现需要输血的出血。食管切除术的狭窄率(5.3%)低于卟啉钠光动力疗法(18.5%),但高于氨基酮戊酸 60mg/kgPDT(1.4%)。各种治疗方法的吞咽困难和疼痛发生率不同,多极电凝(MPEC)报告的发生率最高。光敏反应是光动力疗法特有的不良事件,接受卟啉钠治疗的患者中有 26.4%出现该反应。一些射频消融(RFA)或氩等离子凝固(APC)研究(多次使用)报告的异型增生完全消除率接近 100%。但研究方法和结果描述不充分。其他内镜治疗研究也报告了类似的高异型增生完全消除率。
对于 Barrett 食管和高级别异型增生患者,内镜治疗是食管切除术的安全有效替代方法。遗憾的是,已发表研究的缺陷使得无法确定每种内镜治疗方法的相对有效性。